Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Trevi Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TRVI
Nasdaq
8731
http://www.trevitherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Trevi Therapeutics Inc
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript
- Mar 21st, 2024 2:46 pm
Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials
- Mar 20th, 2024 9:33 pm
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
- Mar 20th, 2024 8:05 pm
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
- Mar 13th, 2024 8:05 pm
private equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last week
- Feb 29th, 2024 10:36 am
Trevi Therapeutics to Participate in Upcoming March Events
- Feb 28th, 2024 12:30 pm
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 12:30 pm
We're Not Very Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Rate
- Jan 19th, 2024 2:24 pm
Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why
- Jan 17th, 2024 5:00 pm
Trevi Therapeutics Provides Business Updates
- Jan 4th, 2024 12:30 pm
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
- Dec 5th, 2023 12:30 pm
Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)
- Nov 30th, 2023 2:35 pm
Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- Nov 14th, 2023 2:55 pm
After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI)
- Nov 14th, 2023 2:35 pm
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript
- Nov 12th, 2023 4:13 pm
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
- Nov 9th, 2023 9:05 pm
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough
- Nov 2nd, 2023 11:30 am
Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
- Nov 1st, 2023 8:05 pm
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis
- Oct 13th, 2023 12:30 pm
Trevi Therapeutics, Inc. (TRVI) Upgraded to Buy: Here's What You Should Know
- Oct 11th, 2023 4:00 pm
Scroll